Omeros (OMER) EBITDA Margin (2010 - 2026)

Omeros' (OMER) quarterly EBITDA Margin came in at 176.09% in Q1 2026, down 132.72% quarter-over-quarter from 75.67% in Q3 2021.

Omeros (OMER) EBITDA Margin (2010 - 2026) Analysis & Trends

Omeros has disclosed EBITDA Margin across 13 years of filings, most recently posting 176.09% for Q1 2026.

EBITDA Margin for Q1 2026 came in at 176.09%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 153.15% (up 5074.0% YoY), and the FY2020 annual result was 187.04%, down 11148.0% from the prior year.
EBITDA Margin came in at 176.09% for Q1 2026 at Omeros, down from 75.67% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 176.09% in Q1 2026 to a low of 176.09% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-6.43%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	38.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Omeros	737.87 Mn	602.55 Mn	9.31 Mn	-176.09%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-176.09%
Sep 30, 2021	-75.67%
Jun 30, 2021	-99.20%
Mar 31, 2021	-166.61%
Dec 31, 2020	-350.57%
Sep 30, 2020	-147.29%
Jun 30, 2020	-246.08%
Mar 31, 2020	-123.34%
Dec 31, 2019	-87.46%
Sep 30, 2019	-55.14%
Jun 30, 2019	-54.02%
Mar 31, 2019	-111.78%
Dec 31, 2018	-106.89%
Sep 30, 2018	-856.60%
Jun 30, 2018	-2,036.01%
Mar 31, 2018	-1,892.57%
Dec 31, 2017	-120.28%
Sep 30, 2017	-34.55%
Jun 30, 2017	-83.72%
Mar 31, 2017	-123.11%